Page last updated: 2024-10-24

candesartan and Aneurysm

candesartan has been researched along with Aneurysm in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Aneurysm: Pathological outpouching or sac-like dilatation in the wall of any blood vessel (ARTERIES or VEINS) or the heart (HEART ANEURYSM). It indicates a thin and weakened area in the wall which may later rupture. Aneurysms are classified by location, etiology, or other characteristics.

Research Excerpts

ExcerptRelevanceReference
"To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes."5.15Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. ( Aldington, S; Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sjølie, AK1
Klein, R1
Porta, M1
Orchard, T1
Fuller, J1
Parving, HH1
Bilous, R1
Aldington, S1
Chaturvedi, N1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area[NCT02834663]Phase 425 participants (Actual)Interventional2016-08-31Completed
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733]Phase 35,238 participants (Actual)Interventional2001-06-30Completed
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694]Phase 34,717 participants (Actual)Interventional2001-08-31Completed
DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720]Phase 31,850 participants (Actual)Interventional2001-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Central Macular Thickness(CMT)

CRT was performed using OCT at each visit. The OCT measured at each visit was analyzed statistically. the CMT compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionum (Mean)
CRT Baseline479.12
CRT Resulte369.12

Perifoveal Non-perfusion Area in FAG (mm²)

Using ImageJ software (version 1.52a) by FAG image. The Perifoveal non-perfusion area in FAG compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionmm2 (Mean)
Perifoveal Non-perfusion Area Baseline2.517
Perifoveal Non-perfusion Area Results2.495

Safety Parameters

Systemic adverse events (MI, CVA, etc), Ocular adverse events (retinal detachment, RPE tear, endophthalmitis, uveitis, vitreous hemorrhage, subretinal hemorrhage, cataract , IOP elevation, etc) at baseline and each visit. (NCT02834663)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Safety Parameters Results0

The Best Corrected Visual Acuity (BCVA)

BCVA was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 6 months. The BCVA compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionletters (Mean)
BCVA Baseline67.6
BCVA Resulte76.36

The Microaneurysm Disappearance Rate

Number of MAs that resolved/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm disappearance rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionmicroaneurysms/month (Mean)
The MA Disappearance Rate Baseline4.40
The MA Disappearance Rate Resulte0.96

The Microaneurysm Formation Rate

number of new MAs detected/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm formation rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionmicroaneurysms/month (Mean)
The MA Formation Rate Baseline2.48
The MA Formation Rate Resulte0.96

The Microaneurysm Turnover

The microaneurysm formation rate + The microaneurysm disappearance rate The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm turnover compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionmicroaneurysms/month (Mean)
The Microaneurysm Turnover Baseline6.88
The Microaneurysm Turnover Results1.92

The Total Number of Microaneurysm

The number of MAs in individual retinas were evaluated during 6 months using fundus photography and FA imaging. The Retmarker software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. Changes in MAs were analyzed statistically. the total number of MAs compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months

Interventionmicroaneurysms (Mean)
Total MA Baseline5.68
Total MA Resulte1.60

Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.

Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.

InterventionParticipants (Number)
Candesartan178
Placebo217

Rate of Change in Urinary Albumin Excretion Rate (UAER).

An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.

Interventionlog (µg/min)/year (Least Squares Mean)
Candesartan0.510
Placebo0.543

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.

InterventionParticipants (Number)
Candesartan161
Placebo182

Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.

3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.

InterventionParticipants (Number)
Candesartan180
Placebo136

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.

InterventionParticipants (Number)
Candesartan192
Placebo193

Rate of Change in Urinary Albumin Excretion Rate (UAER).

An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.

Interventionlog (µg/min)/1000 year (Least Squares Mean)
Candesartan656
Placebo718

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.

InterventionParticipants (Number)
Candesartan127
Placebo124

Number of Participants With a Regression of Diabetic Retinopathy.

Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years

InterventionParticipants (Number)
Candesartan140
Placebo139

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.

InterventionParticipants (Number)
Candesartan110
Placebo107

Rate of Change in Urinary Albumin Excretion Rate (UAER).

An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.

Interventionlog (µg/min)/year (Least Squares Mean)
Candesartan0.569
Placebo0.642

Trials

1 trial available for candesartan and Aneurysm

ArticleYear
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet

2011